ERIN SINRAM: Open Payments
NPI 1093093361 · FAIRBANK, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$750 in 40 payments from 10 companies in 2025. Trend: 2023 $725 · 2024 $1,069 · 2025 $750
Food & beverage: $750
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 12 | $226 |
| ABBVIE INC. | 6 | $114 |
| Novo Nordisk Inc | 4 | $77 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $74 |
| Exact Sciences Corporation | 3 | $52 |
| Amgen Inc. | 3 | $46 |
| Viatris Specialty LLC | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: JARDIANCE, MOUNJARO, QULIPTA, VOQUEZNA, REPATHA, Ozempic, YUPELRI, VRAYLAR.
Industry payments across IA — which companies pay providers there.
